Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z3KETJG
via IFTTT